Machine learning-based integration develops a metabolism-derived consensus model for improving immunotherapy in pancreatic cancer
Open Access
- 22 September 2023
- journal article
- research article
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 11 (9) , e007466
Abstract
Background Pancreatic cancer (PAC) is one of the most malignant cancer types and immunotherapy has emerged as a promising treatment option. PAC cells undergo metabolic reprogramming, which is thought to modulate the tumor microenvironment (TME) and affect immunotherapy outcomes. However, the metabolic landscape of PAC and its association with the TME remains largely unexplored. Methods We characterized the metabolic landscape of PAC based on 112 metabolic pathways and constructed a novel metabolism-related signature (MBS) using data from 1,188 patients with PAC. We evaluated the predictive performance of MBS for immunotherapy outcomes in 11 immunotherapy cohorts from both bulk-RNA and single-cell perspectives. We validated our results using immunohistochemistry, western blotting, colony-formation assays, and an in-house cohort. Results MBS was found to be negatively associated with antitumor immunity, while positively correlated with cancer stemness, intratumoral heterogeneity, and immune resistant pathways. Notably, MBS outperformed other acknowledged signatures for predicting immunotherapy response in multiple immunotherapy cohorts. Additionally, MBS was a powerful and robust biomarker for predicting prognosis compared with 66 published signatures. Further, we identified dasatinib and epothilone B as potential therapeutic options for MBS-high patients, which were validated through experiments. Conclusions Our study provides insights into the mechanisms of immunotherapy resistance in PAC and introduces MBS as a robust metabolism-based indicator for predicting response to immunotherapy and prognosis in patients with PAC. These findings have significant implications for the development of personalized treatment strategies in patients with PAC and highlight the importance of considering metabolic pathways and immune infiltration in TME regulation.Keywords
Funding Information
- National Natural Science Foundation of China (81372255, 81902523)
This publication has 54 references indexed in Scilit:
- Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer ProgressionCell, 2015
- Broad Anti-tumor Activity of a Small Molecule that Selectively Targets the Warburg Effect and LipogenesisCancer Cell, 2015
- PD-L1 Expression as a Predictive Biomarker in Cancer ImmunotherapyMolecular Cancer Therapeutics, 2015
- Tumor glycolysis as a target for cancer therapy: progress and prospectsMolecular Cancer, 2013
- The sva package for removing batch effects and other unwanted variation in high-throughput experimentsBioinformatics, 2012
- Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapyNature Medicine, 2011
- Indoleamine 2,3-dioxygenase controls conversion of Foxp3+ Tregs to TH17-like cells in tumor-draining lymph nodesBlood, 2009
- The mTOR Kinase Differentially Regulates Effector and Regulatory T Cell Lineage CommitmentImmunity, 2009
- GCN2 Kinase in T Cells Mediates Proliferative Arrest and Anergy Induction in Response to Indoleamine 2,3-DioxygenaseImmunity, 2005
- On the Origin of Cancer CellsScience, 1956